30 results about "Chlorphenamine" patented technology

The invention discloses a high-performance liquid chromatography method for determining the component content of Compound Polygonum cuspidatum Ammonia Tablets, which adopts 50% methanol solution for ultrasonic extraction, uses acetonitrile-0.1% phosphoric acid solution as mobile phase, and Kromasil 100-5 C 18 Chromatographic column separation, ultraviolet detection wavelength is 222nm, 326nm. The method adopts high-performance liquid chromatography-ultraviolet spectroscopy dual-wavelength method to realize the simultaneous determination of two chemical components of paracetamol and chlorpheniramine maleate and the main components of Senecio dry paste, chlorogenic acid, and Polygonum cuspidatum dry paste. The content detection of polydatin, the main component, has the characteristics of rapid pretreatment, good separation between the four components and other components, and good accuracy. The invention provides a reference for better evaluating and controlling the quality of compound polygonum cuspidatum and ammonia-min tablets.

The invention discloses application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus. The application comprises the following steps of: first, performing an antivirus experiment by selecting the chlorpheniramine maleate with completely non-toxic concentration, wherein the result shows that the low molecular weight compound has remarkable antiviral activity and has dose-dependent correlation; then, analyzing the anti-influenza virus action cycle of chlorpheniramine maleate, wherein the result shows that chlorpheniramine maleate mainly inhibits the early virus infection events of virus adsorption, entry and the like; and finally, detecting the antiviral activity of chlorpheniramine maleate on different types or subtypes of influenza virus, wherein the result shows that chlorpheniramine maleate can inhibit the replication of all detection virus strains and has a dose-dependent effect, and shows that the anti-influenza virus activity of chlorpheniramine maleate has certain broad spectrum. Therefore, chlorpheniramine maleate disclosed by the invention can be developed as a new anti-influenza virus medicament, and provides a new way and a new means for treating the influenza virus.

The present invention provides a powder pharmaceutical formulations for treating infantile diarrhea which overcomes weak pocket of other medicament for treating the disease. The powder pharmaceutical formulation is prepared by raw materials as follows: biofermin 0.1-1 g, compound diphenoxylate 0.25-2.5 mg, acetylsalicylic acid 0.3-0.15 g, chlorphenamine 0.04-0.2 mg and hydrochlorothiazidum tablet1-5 mg, the above medicine are grinded to dead small, then are measured and packed for obtaining the powder pharmaceutical formulation. The powder pharmaceutical formulation for treating infantile diarrhea is used about twenty years and is consulted by patients 10000 times, wherein, males 5500 times, females 4500 times, curative rate 98% and efficiency rate 100%.

The invention discloses codein and chlorphenamine compound sustained release capsules. The sustained release granules are made from the following raw materials by weight: 10-11.1 parts of codein, 2-2.2 parts of chlorphenamine, 1-2 parts of a lubricant, 18.9-86 parts of a sustained release matrix material and 0-12.4 parts of a filling agent. The sustained release matrix material is two or three ofhydroxypropyl emthylcellulose, acrylic resin and ethyl cellulose, wherein, the acrylic resin and the ethyl cellulose totally accounts for 10.9-31.5%. The capsules are obtained by the following steps:evenly mixing the codein, the chlorphenamine and the sustained release matrix material; adding a binder to prepare a soft material and sieving with a 6-24-mesh sieve; preparing damp granules, drying and granulating; and adding the lubricant, evenly mixing and then encapsulating to obtain the finished product.

The present invention relates to medicine with organic effective component, and aims at one kind of ointment compounded with anisodamine and capable of curing frostbite and sclerema neonatorum in relatively short time. The ointment is compounded with anisodamine in 15-20 wt% and chlorphenamine 5-15 wt% except medical vaseline. The supplementary material includes metronidazole and / or prednisone and proper amount of vitamin E. The preparation process includes heating vaseline, mixing with other components, cooling and packing in box. The present invention has simple preparation process, low cost, convenient use and obvious treating effect.

The invention provides a process for preparing paracetamol pseudoephedrine hydrochloride and chlorphenamine malease orally disintegrating tablets, mixing paracetamol with bulking agent for granulating, making solution from pseudoephedrine hydrochloride, chlorphenamine maleate and spray packaging material, coating onto obtained paracetamol particles, then dressing to obtain flavor masked particles, finally mixing the particles with other adjuvant and tabletting.

The present invention relates to a kind of plaster for treating protrusion of lumbar intervertebral disc and its preparation process. The plaster is prepared with prepared with over thirty kinds of Chinese medicinal materials, including nux vomica seed, momordica seed, clematis root, Radix Aconiti Brachpodi, aconite root, etc. and Western medicine chlorphenamine, and through frying partial of its Chinese medicinal materials in oil, filtering, mixing and other steps. It is pasted on to the affected part to treat protrusion of lumbar intervertebral disc.

The invention provides a compound preparation which can comprehensively overcome the symptom relative to cold and can slowly release all the active ingredients. The slow-release preparation of the invention not only can overcome the symptom relative to cold but also can perform the synergistic function of compound medicine. The three active ingredients of the slow-release preparation of the invention can be released and absorbed synchronously so as to acquire expected releasing action in human body. The preparation of the invention can be taken for two times per day, namely, can be taken for one time in morning and evening instead of taking four times per day in the past. The preparation of the invention is characterized by less taking times, slow release in body, stable blood concentration, small fluctuation, high bioavailability and high safety.